KPC Pharmaceuticals Inc (600422) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has a cash flow conversion efficiency ratio of -0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-16.66 Million ≈ $-2.44 Million USD) by net assets (CN¥6.86 Billion ≈ $1.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
KPC Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how KPC Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KPC Pharmaceuticals Inc (600422) total liabilities for a breakdown of total debt and financial obligations.
KPC Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPC Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AirAsia X Bhd
KLSE:5238
|
0.178x |
|
GRIPM Advanced Materials Co. Ltd. A
SHG:688456
|
0.060x |
|
Yangzhou Seashine New Materials Co
SHE:300885
|
0.030x |
|
Hana Materials Inc
KQ:166090
|
0.049x |
|
L&C Bio Co. Ltd
KQ:290650
|
0.014x |
|
Trican Well Service Ltd.
TO:TCW
|
0.127x |
|
Electra Real Estate Ltd
TA:ELCRE
|
-0.016x |
|
GuangDong Leary New Material Technology Co. Ltd. A
SHG:688683
|
0.046x |
Annual Cash Flow Conversion Efficiency for KPC Pharmaceuticals Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of KPC Pharmaceuticals Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see 600422 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥6.75 Billion ≈ $987.19 Million |
CN¥808.07 Million ≈ $118.25 Million |
0.120x | +84.22% |
| 2023-12-31 | CN¥5.48 Billion ≈ $801.39 Million |
CN¥356.08 Million ≈ $52.11 Million |
0.065x | +31.69% |
| 2022-12-31 | CN¥5.14 Billion ≈ $752.51 Million |
CN¥253.90 Million ≈ $37.15 Million |
0.049x | -3.07% |
| 2021-12-31 | CN¥4.94 Billion ≈ $722.92 Million |
CN¥251.63 Million ≈ $36.82 Million |
0.051x | -42.81% |
| 2020-12-31 | CN¥4.60 Billion ≈ $673.51 Million |
CN¥409.94 Million ≈ $59.99 Million |
0.089x | -10.12% |
| 2019-12-31 | CN¥4.33 Billion ≈ $634.22 Million |
CN¥429.50 Million ≈ $62.85 Million |
0.099x | +11.14% |
| 2018-12-31 | CN¥3.95 Billion ≈ $577.79 Million |
CN¥352.07 Million ≈ $51.52 Million |
0.089x | +38.74% |
| 2017-12-31 | CN¥3.77 Billion ≈ $552.21 Million |
CN¥242.53 Million ≈ $35.49 Million |
0.064x | -25.39% |
| 2016-12-31 | CN¥3.61 Billion ≈ $528.55 Million |
CN¥311.16 Million ≈ $45.53 Million |
0.086x | -39.71% |
| 2015-12-31 | CN¥3.34 Billion ≈ $488.14 Million |
CN¥476.62 Million ≈ $69.74 Million |
0.143x | -22.76% |
| 2014-12-31 | CN¥2.05 Billion ≈ $299.93 Million |
CN¥379.13 Million ≈ $55.48 Million |
0.185x | +43.65% |
| 2013-12-31 | CN¥1.88 Billion ≈ $274.98 Million |
CN¥241.97 Million ≈ $35.41 Million |
0.129x | -36.22% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.63 Million |
CN¥213.33 Million ≈ $31.22 Million |
0.202x | +32.09% |
| 2011-12-31 | CN¥917.52 Million ≈ $134.26 Million |
CN¥140.24 Million ≈ $20.52 Million |
0.153x | +38.02% |
| 2010-12-31 | CN¥820.15 Million ≈ $120.01 Million |
CN¥90.82 Million ≈ $13.29 Million |
0.111x | -36.41% |
| 2009-12-31 | CN¥738.35 Million ≈ $108.04 Million |
CN¥128.57 Million ≈ $18.81 Million |
0.174x | +27.48% |
| 2008-12-31 | CN¥670.50 Million ≈ $98.12 Million |
CN¥91.59 Million ≈ $13.40 Million |
0.137x | -33.29% |
| 2007-12-31 | CN¥635.17 Million ≈ $92.94 Million |
CN¥130.06 Million ≈ $19.03 Million |
0.205x | +95.19% |
| 2006-12-31 | CN¥583.86 Million ≈ $85.44 Million |
CN¥61.25 Million ≈ $8.96 Million |
0.105x | +135.35% |
| 2005-12-31 | CN¥588.02 Million ≈ $86.05 Million |
CN¥-174.52 Million ≈ $-25.54 Million |
-0.297x | -7626.53% |
| 2004-12-31 | CN¥723.20 Million ≈ $105.83 Million |
CN¥-2.78 Million ≈ $-406.50K |
-0.004x | -104.14% |
| 2003-12-31 | CN¥659.95 Million ≈ $96.57 Million |
CN¥61.23 Million ≈ $8.96 Million |
0.093x | +204.86% |
| 2002-12-31 | CN¥571.17 Million ≈ $83.58 Million |
CN¥17.38 Million ≈ $2.54 Million |
0.030x | -74.60% |
| 2001-12-31 | CN¥559.74 Million ≈ $81.91 Million |
CN¥67.07 Million ≈ $9.81 Million |
0.120x | +39.91% |
| 2000-12-31 | CN¥557.64 Million ≈ $81.60 Million |
CN¥47.76 Million ≈ $6.99 Million |
0.086x | -79.96% |
| 1999-12-31 | CN¥140.93 Million ≈ $20.62 Million |
CN¥60.24 Million ≈ $8.81 Million |
0.427x | -- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more